CN206342739U - Connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices - Google Patents
Connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices Download PDFInfo
- Publication number
- CN206342739U CN206342739U CN201620733453.XU CN201620733453U CN206342739U CN 206342739 U CN206342739 U CN 206342739U CN 201620733453 U CN201620733453 U CN 201620733453U CN 206342739 U CN206342739 U CN 206342739U
- Authority
- CN
- China
- Prior art keywords
- blood
- catheter
- upstream
- bioartificial liver
- downstream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model is related to a kind of connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices, including：Cyto-centrifuge；Bioartificial liver devices；The the first upstream blood catheter and the first downstream blood catheter being connected with bioartificial liver devices；With the second upstream blood catheter and the second downstream blood catheter being connected with cyto-centrifuge；Wherein described second upstream blood catheter and the second downstream blood catheter are connected in second entrance point and second outlet point respectively with first upstream blood catheter, and second outlet point than second entrance point closer to the bioartificial liver devices.
Description
Technical field
The application is related to medical instruments field, more particularly, to a kind of blood processor with series parallel structure.
Background technology
Hepatic failure patients carry out autologous peripheral blood stemcell transplant, need to carry out stem cell collection, however, such conditions of patients weight,
AISS such as bioartificial liver is generally required to be treated.Normal practice is that patient receives single bio-artificial
Liver is treated, and first sets up extracorporal circulatory system path, and patient is connected into bioartificial liver's treatment machine, carries out bioartificial liver's treatment, when
Between about 2-4 hours；Autologous peripheral blood stem cells collection is then acquired using single blood cell separator, need to re-establish body
External circulation path, it is time-consuming about to need 2-3 hours.
Bioartificial liver, stem cell collection are originally the clinical technologies being used alone, and need to be done for hepatic failure patients
, it is necessary to which using two kinds of therapeutic modalities, the shortcoming carried out respectively is that patient need to set up extracorporal circulatory system path repeatedly during cell collection,
Repeatedly addition anti-coagulants, and external anti-freezing increased risk, is lengthened while treatment is time-consuming, causes the discomfort and clinical wind of patient
Danger.
Utility model content
The purpose of this utility model is the hepatic failure patients for needing progress stem cell collection and bioartificial liver
Treatment operates the method and treatment method of the device, by biological people there is provided a kind of blood processor with series parallel structure
Work liver device and cyto-centrifuge connection, while bioartificial liver, two treatments of stem cell collection are carried out, so as to improve treatment
Efficiency, reduces patient's Operative risk.
The utility model includes herein below：
A kind of blood processor of embodiment 1., it is characterised in that including：
Cyto-centrifuge；
Bioartificial liver devices；
The the first upstream blood catheter and the first downstream blood catheter being connected with bioartificial liver devices；With
The the second upstream blood catheter and the second downstream blood catheter being connected with cyto-centrifuge；Wherein
Second upstream blood catheter and the second downstream blood catheter and first upstream blood catheter are respectively the
Two entrances and the connection of second outlet point, and second outlet point than second entrance point closer to the bioartificial liver
Device.
Blood processor of the embodiment 2. according to embodiment 1, it is characterised in that also include：With described
The anti-coagulants injection conduit of one upstream blood catheter connection.
Blood processor of the embodiment 3. according to embodiment 1, it is characterised in that also include：With described
The displacement liquid injection conduit of one downstream blood catheter connection.
Blood processor of the embodiment 4. according to any one of embodiment 1-3, it is characterised in that wherein institute
State cyto-centrifuge and be configured to blood of the separation from the second upstream blood catheter and obtain the second separation blood and dry thin
Born of the same parents, and the second separation blood is entered the second downstream blood catheter.
Blood processor of the embodiment 5. according to any one of embodiment 1-3, it is characterised in that wherein institute
State bioartificial liver devices to be configured to carry out bioartificial liver's processing to the blood from the first upstream blood catheter, and make
Blood through processing enters the first downstream blood catheter.
Blood processor of the embodiment 6. according to any one of embodiment 1-3, it is characterised in that also wrap
Include：The second flow regulation meter being connected with second upstream blood catheter.
Blood processor of the embodiment 7. according to embodiment 1 or 2, it is characterised in that also include：With it is described
The first flow regulation meter of first upstream blood catheter connection, the first flow regulation meter is located under the second outlet point
Trip.
Blood processor of the embodiment 8. according to embodiment 2, it is characterised in that also including with the anti-freezing
The anti-coagulants injector of agent injection conduit connection, it is configured for injecting anti-coagulants.
Blood processor of the embodiment 9. according to embodiment 3, it is characterised in that also including with the displacement
The displacement liquid injector of liquid injection conduit connection.
Blood processor of the embodiment 10. according to embodiment 1, it is characterised in that the blood treatment dress
Blood volume in putting is less than 500ml.
A kind of control system for being used to operate the blood processor any one of embodiment 1-10 of embodiment 11.
System, it is characterised in that the control system includes software and hardware, the control system is configured to operate the blood as follows
Liquid processing device：The Part I of pending blood is flowed through the first upstream blood catheter and enter bioartificial liver devices, and
And the Part II of pending blood enters the second upstream blood catheter simultaneously from the first upstream blood catheter in second entrance point
Into cyto-centrifuge；
The Part II of pending blood is carried out separating treatment and obtains separated second separation by cyto-centrifuge
Blood, the second separation blood is merged through the second downstream blood catheter in second outlet point with the Part I of pending blood
The blood merged, the blood of merging enters bioartificial liver devices,
The blood of merging is carried out bioartificial liver's processing by bioartificial liver devices.
The utility model is also comprising such embodiment：
A kind of blood processor, it is characterised in that including：
Cyto-centrifuge；
Bioartificial liver devices；
The the first upstream blood catheter and the first downstream blood catheter being connected with bioartificial liver devices；With
The the second upstream blood catheter and the second downstream blood catheter being connected with cyto-centrifuge；Wherein
Second upstream blood catheter and the second downstream blood catheter and first downstream blood catheter are respectively the
Two entrances and the connection of second outlet point, and second entrance point than second outlet point closer to the bioartificial liver
Device.
By means of the technical solution of the utility model, for needing to carry out stem cell transplantation and the hepatic failure of bioartificial liver
The treatment of patient, it is only necessary to set up an extracorporeal circulation of blood, while two treatments of bioartificial liver and stem cell collection are carried out,
So as to shorten treatment time, therapeutic efficiency is improved, patient's Operative risk is reduced.
Brief description of the drawings
In order to illustrate more clearly of the technical scheme of the embodiment of the present disclosure, the accompanying drawing of embodiment will be simply situated between below
Continue, it should be apparent that, drawings in the following description merely relate to some embodiments of the present disclosure, rather than limitation of this disclosure.
Fig. 1 is a kind of schematic diagram of embodiment of the application.
Fig. 2 is a kind of schematic diagram for being used to operate the control system of blood processor.
In figure, reference has following meanings：
D：Cyto-centrifuge；F：Bioartificial liver devices；
ABEF：First upstream blood catheter；B：Second entrance point；E：Second outlet point；
FGH：First downstream blood catheter；G：Displacement liquid injects conduit access point；
BD：Second upstream blood catheter；
DE：Second downstream blood catheter；
P1：First flow regulation meter；
P2：Second flow regulation meter；
C：Anti-coagulants injects conduit access point；
11：Control system.
Embodiment
To make the purpose, technical scheme and advantage of the embodiment of the present disclosure clearer, below in conjunction with the embodiment of the present disclosure
Accompanying drawing, the technical scheme to the embodiment of the present disclosure is clearly and completely described.Obviously, described embodiment is this public affairs
A part of embodiment opened, rather than whole embodiments.Based on described embodiment of the disclosure, ordinary skill
The every other embodiment that personnel are obtained on the premise of without creative work, belongs to the scope of disclosure protection.
Hepatic failure patients carry out autologous peripheral blood stemcell transplant, need to carry out stem cell collection, however, such conditions of patients weight,
Generally require to be supported treatment by bioartificial liver.Normal practice is that patient receives single bioartificial liver's treatment,
Extracorporal circulatory system path is first set up, patient is connected into bioartificial liver's treatment machine, bioartificial liver's treatment, time about 2-4 is carried out
Hour；Autologous peripheral blood stem cells collection is then acquired using single blood cell separator, need to re-establish extracorporal circulatory system
Path, it is time-consuming about to need 2-3 hours.
Bioartificial liver, which is mainly, is implanted into the liver cell of in vitro culture in bioreactor, will using In vitro perfusion system
Blood is introduced into reactor, and biological agent is carried out with the liver cell in reactor, to complete to synthesize, the function such as is metabolized.With group
Knit culture technique, Protocols in Molecular Biology constantly to make a breakthrough, especially stem cell is separately cultured and Techniques of preserving, and stem cell is big
Scale evaluation technology and bioreactor are increasingly ripe and successfully develop, and also have developed using liver cell as bioactive ingredients
Biotype artificial liver (also referred to as bioartificial liver).There is provided liver by the stem cell in bioreactor by bioartificial liver
The function such as secretion, metabolism, bioconversion and removing toxic substances, theoretically, can almost replace the repertoire of liver.It is general and
Speech, bioartificial liver includes liver cell source and bioreactor.
The acquisition method of peripheral hematopoietic stem cells (PBSC) can use the single of cyto-centrifuge separation collection peripheral blood
Nucleus component.Many program separation using separation lymphocyte.The descending big venipuncture of ordinary circumstance, foundation is followed in vitro
Ring is acquired.VPV during collection adult is 50-60ml/min, and 4-6 circulations (about 2-3h), separation are separated every time
The total measurement (volume) 9L of blood, according to situation it is continuous or the next day gather.
Traditional bioartificial liver, stem cell collection individually carry out being respectively provided with preferable security and effect.Bio-artificial
There is provided the functions such as the secretion of liver, metabolism, bioconversion and removing toxic substances by the liver cell in bioreactor for liver.Theoretically
Say, bioartificial liver can almost substitute the repertoire of liver.The acquisition method of peripheral hematopoietic stem cells (PBSC) belongs at present
Ripe clinical application technique, can preferably collect the cell quantity of target requirement amount according to demand.
Bioartificial liver, stem cell collection are originally the clinical technologies being used alone, and need to be done for hepatic failure patients
, it is necessary to which using two kinds of therapeutic modalities, the shortcoming carried out respectively is that patient need to set up extracorporal circulatory system path repeatedly during cell transplantation,
External anti-freezing increased risk, the time-consuming addition for the treatment of, causes the discomfort and clinical risk of patient.
The purpose of this utility model is the hepatic failure patients for needing progress stem cell transplantation and bioartificial liver
Treatment operates the method and treatment method of the device, by biological people there is provided a kind of blood processor with series parallel structure
Work liver device and cyto-centrifuge connection, while bioartificial liver, two treatments of stem cell collection are carried out, so as to improve treatment
Efficiency, reduces patient's Operative risk.
Fig. 1 shows a kind of blood processor, and it includes：
Cyto-centrifuge D；
Bioartificial liver devices F；
The the first upstream blood catheter (ABEF) and the first downstream blood catheter (FGH) being connected with bioartificial liver devices；
With
The the second upstream blood catheter (BD) and the second downstream blood catheter (DE) being connected with cyto-centrifuge；Wherein
Second upstream blood catheter and the second downstream blood catheter and first upstream blood catheter are respectively the
Two entrances (B) and second outlet point (E) connection, and second outlet point (E) than second entrance point (B) closer to institute
State bioartificial liver devices.
In Fig. 1, conduit makes indicated by the solid line, and the arrow wherein on solid line represents the flow direction of material in conduit.
The blood processor is used for by will be connected to for the second blood circulation that haemocyte is separated with parallel way
First sanguimotor upstream of bioartificial liver's treatment, so that, it is only necessary to setting up an extracorporeal circulation of blood can make
Obtain and carry out haemocyte separation and bioartificial liver's treatment simultaneously, and because the time of haemocyte separation circulation is shorter, by means of
This device, haemocyte separation circulation can be opened and closed at any time, and without influenceing bioartificial liver's circulation, result is without individually setting up
Haemocyte separation circulation, and saved the time of haemocyte separation circulation, therapeutic efficiency is improved, patient's treatment wind is reduced
Danger.
In this application, the circulation being connected with bioartificial liver devices is referred to as first circulation or the first blood circulation.
In the application, the circulation being connected with cyto-centrifuge is referred to as second circulation or the second blood circulation.
In some instances, the blood processor, in addition to：The anti-freezing being connected with first upstream blood catheter
Conduit is injected in agent.In embodiments herein, it is only necessary to set anti-coagulants to inject conduit at the first upstream blood catheter, from this
Conduit adds anti-coagulants, it is possible to so that the blood of whole human body is by test tube of hepari (anti-coagulated processing), so that whole blood circulation
Pipeline disclosure satisfy that the requirement of anti-freezing.
Anti-coagulants injection conduit can certainly be connected on the blood catheter of second upstream.In some instances, institute
State and anti-coagulants injection conduit is not connected on the second upstream blood catheter.
In some instances, in the blood processor, the cyto-centrifuge is configured to separation and come from
Stem cell in the blood of second upstream blood catheter obtains the second separation blood, and the second separation blood is entered the second downstream
Conduit.
In some instances, in the blood processor, the bioartificial liver devices be configured to from
The blood of first upstream blood catheter carries out bioartificial liver's processing, and the blood through processing is led into the first downstream blood
Pipe.
In some instances, the blood processor also includes：Second be connected with second upstream blood catheter
Flow-controlling meter P2.
In some instances, the blood processor, in addition to：First be connected with first upstream blood catheter
Flow-controlling meter P1, the first flow regulation meter P1 are located at the downstream of the second outlet point (E).
In some instances, the blood volume in the blood processor is less than 500ml, preferably shorter than 400ml, more excellent
Choosing is less than 300ml.Make the blood volume in whole blood processor it is relatively low be in order to patient can for ability to bear,
For normal people, discomfort occurs when may work as blood missing (extracorporal circulatory system) more than 500ml, however, for hepatopathy
Patient, possible blood is circulated in vitro just occurs malaise symptoms before reaching 500ml, therefore, in the blood processor
Blood volume it is more low better, preferably shorter than 400ml.
Embodiments herein also provides the method for operating above-described blood processor, including：
The Part I of pending blood is set to flow through the first upstream blood catheter into bioartificial liver devices F, and
The Part II of pending blood enters the second upstream blood catheter simultaneously from the first upstream blood catheter in second entrance point (B)
Into cyto-centrifuge D；
The Part II of pending blood is carried out separating treatment and obtains separated second separation by cyto-centrifuge D
Blood, the second separation blood is merged through the second downstream blood catheter in second outlet point with the Part I of pending blood
The blood merged, the blood of merging enters bioartificial liver devices F,
The blood of merging is carried out bioartificial liver's processing by bioartificial liver devices F.
In some instances, methods described also includes：Conduit is injected to the second upstream blood catheter by the anti-coagulants
In pending blood Part II in add anti-coagulants.
In some instances, methods described also includes：Conduit is injected to the first downstream blood catheter by the displacement liquid
In blood in add displacement liquid.Described displacement liquid can include human serum albumin.
In some instances, in the process, the cyto-centrifuge is configured to separation and comes from the second upstream
Stem cell in the blood (Part II of pending blood) of blood catheter obtains the second separation blood, and makes the second separation
Blood enters the second downstream blood catheter.
In some instances, the bioartificial liver devices are configured to the blood from the first upstream blood catheter
Bioartificial liver's processing is carried out, and the blood through processing is entered the first downstream blood catheter.
In some instances, methods described also includes：Adjust the second flow regulation meter P2 and first flow regulation meter
At least one in P1, so that the flow in flow and the first blood circulation in the second blood circulation meets outer circulation blood
The requirement of flow velocity.
In some instances, methods described also includes in advance entering described device (including whole pipeline) using heparin saline
Row pipeline pre-flush.In the running of described device, only it can just be realized in the first upstream blood catheter addition anti-coagulants
The test tube of hepari of overall circulation, the process of overall test tube of hepari is reached by human circulation, without anti-freezing in second circulation
Agent, so as to reduce the consumption of anti-coagulants (heparin).In this application, test tube of hepari and it is anti-coagulated have identical implication, all
Being directed to add anti-coagulants such as heparin so as to reach in blood makes blood noncondensing effect during handling in vitro.
In some examples of methods described, the cyto-centrifuge is configured to separation and comes from the second upstream blood
Stem cell in the blood (Part II of pending blood) of conduit obtains the second separation blood, and makes the second separation blood
Into the second downstream blood catheter.
In some examples of methods described, the bioartificial liver devices are configured to from the first upstream blood
The blood of conduit carries out bioartificial liver's processing, and the blood through processing is entered the first downstream blood catheter.
In some instances, methods described also includes：Adjust the second flow regulation meter P2 and first flow regulation meter
At least one in P1, so that flow and pressure reach balance in whole circulation.
In some instances, methods described also includes：The step of starting described device：Second circulation is set to be in closing first
(it can count P2 to state for example, by closing the second flow regulation, or folder closes the pipeline and first of the second circulation
The gateway of the line connection of circulation is completed), then start first circulation, proceed by bioartificial liver's processing, treat blood flow
After dynamic stabilization (such as when P1 is maintained at more than 80ml/min), starting second circulation, (it can be described for example, by opening
Second flow regulation meter P2, or remove at the gateway of the pipeline of the second circulation and the line connection of first circulation
Clip is completed), realize stem cell collection.
In some instances, methods described also includes：The step of stopping described device：Terminate second circulation first, folder is closed
Second circulation entrance, into red blood cell program is returned, after red blood cell in second circulation pipeline is returned, folder closes second circulation and gone out
Mouthful, cyto-centrifuge shutdown, first circulation proceeds in the process；Then first circulation is terminated.
As shown in Fig. 2 the application also provides a kind of control system 11 for being used to operate described blood processor, it is special
Levy and be, the control system includes software and hardware, the control system is configured to realize method as described above.Figure
2 be schematic diagram, and the specific part of control system is not shown.However, it should be appreciated by those skilled in the art that according to the application
The information provided at present, forms the conventional technical means that the control system is those skilled in the art.Therefore, Ren Heneng
Enough realize the control system of methods described all in the protection domain of the application.
The application also provides a kind of control system for being used to operate described blood processor, it is characterised in that described
Control system includes software and hardware, and the control system is configured to operate the blood processor as follows：Make pending
The Part I of blood flow through the first upstream blood catheter and enter bioartificial liver devices, and the second of pending blood
Part enters the second upstream blood catheter in second entrance point from the first upstream blood catheter and enters cyto-centrifuge；
The Part II of pending blood is carried out separating treatment and obtains separated second separation by cyto-centrifuge
Blood, the second separation blood is merged through the second downstream blood catheter in second outlet point with the Part I of pending blood
The blood merged, the blood of merging enters bioartificial liver devices,
The blood of merging is carried out bioartificial liver's processing by bioartificial liver devices.
Embodiment
Using the device shown in Fig. 1,10 patients are treated.As a result it is as shown in the table.
In upper table,
" collection mononuclearcell number (/L) " refers to PMNC (Peripheral blood
Mononuclear cell, PBMC) be the cell in peripheral blood with single core concentration, including lymphocyte, monocyte
With the peripheral blood hematopoietic stem cells being characterized with CD34+ molecular labelings.
It is the mark of hemopoietic stem cell surface that " CD34+ cell numbers (/L) ", which refers to CD34, and CD34+ cell numbers refer to Hematopoietic Stem
The concentration of cell
" treatment time (h) needed for theoretical " refers to：Traditional treatment is carried out needed for bioartificial liver and stem cell collection respectively
The summation for the treatment of time.
" actual therapeutic spends the time (h) " refers to：Being had altogether using this example progress bioartificial liver and stem cell collection is needed
The real time wanted.
Measurement by the biochemical indicator to patient shows, patient is treated using the blood processor of the disclosure
Compared with the method treated respectively using two traditional steps, therapeutic effect does not have notable difference, but but shortens treatment
Time, alleviate the pain of patient.
Described above is only the exemplary embodiment of the disclosure, not for the protection domain of the limitation disclosure, this public affairs
The protection domain opened is determined by appended claim.
Claims (11)
1. a kind of blood processor, it is characterised in that including：
Cyto-centrifuge；
Bioartificial liver devices；
The the first upstream blood catheter and the first downstream blood catheter being connected with bioartificial liver devices；With
The the second upstream blood catheter and the second downstream blood catheter being connected with cyto-centrifuge；Wherein
Second upstream blood catheter and the second downstream blood catheter enter second respectively with first upstream blood catheter
Mouth point and second outlet point are connected, and second outlet point is filled than second entrance point closer to the bioartificial liver
Put.
2. blood processor according to claim 1, it is characterised in that also include：Led with first upstream blood
The anti-coagulants injection conduit of pipe connection.
3. blood processor according to claim 1, it is characterised in that also include：Led with first downstream blood
The displacement liquid injection conduit of pipe connection.
4. the blood processor according to any one of claim 1-3, it is characterised in that wherein described haemocyte separation
Device is configured to blood of the separation from the second upstream blood catheter and obtains the second separation blood and stem cell, and makes second point
Enter the second downstream blood catheter from blood.
5. the blood processor according to any one of claim 1-3, it is characterised in that wherein described bioartificial liver
Device is configured to carry out bioartificial liver's processing to the blood from the first upstream blood catheter, and makes the blood through processing
Into the first downstream blood catheter.
6. the blood processor according to any one of claim 1-3, it is characterised in that also include：With described second
The second flow regulation meter of upstream blood catheter connection.
7. blood processor according to claim 1 or 2, it is characterised in that also include：With first upstream blood
The first flow regulation meter of conduit connection, the first flow regulation meter is positioned at the downstream of the second outlet point.
8. blood processor according to claim 2, it is characterised in that also including connecting with anti-coagulants injection conduit
The anti-coagulants injector connect, it is configured for injecting anti-coagulants.
9. blood processor according to claim 3, it is characterised in that also including connecting with displacement liquid injection conduit
The displacement liquid injector connect.
10. blood processor according to claim 1, it is characterised in that the blood in the blood processor holds
Amount is less than 500ml.
11. a kind of control system that the blood processor any one of 1-10 is required for operational rights, its feature exists
In the control system includes software and hardware, and the control system is configured to operate the blood processor as follows：
The Part I of pending blood is flowed through the first upstream blood catheter and enter bioartificial liver devices, and pending blood
The Part II of liquid enters the second upstream blood catheter in second entrance point from the first upstream blood catheter and enters haemocyte minute
From device；
The Part II of pending blood is carried out separating treatment and obtains separated second separation blood by cyto-centrifuge,
Second separation blood is merged through the second downstream blood catheter in second outlet point with the Part I of pending blood and obtained
The blood of merging, the blood of merging enters bioartificial liver devices,
The blood of merging is carried out bioartificial liver's processing by bioartificial liver devices.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620733453.XU CN206342739U (en) | 2016-07-12 | 2016-07-12 | Connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620733453.XU CN206342739U (en) | 2016-07-12 | 2016-07-12 | Connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN206342739U true CN206342739U (en) | 2017-07-21 |
Family
ID=59320219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201620733453.XU Expired - Fee Related CN206342739U (en) | 2016-07-12 | 2016-07-12 | Connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN206342739U (en) |
-
2016
- 2016-07-12 CN CN201620733453.XU patent/CN206342739U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Floege et al. | β2-microglobulin kinetics during haemodialysis and haemofiltration | |
| US6858146B1 (en) | Artificial liver apparatus and method | |
| Ding et al. | The development of a new bioartificial liver and its application in 12 acute liver failure patients | |
| Ikomi et al. | Recent advance in lymph dynamic analysis in lymphatics and lymph nodes | |
| TW200538172A (en) | Metabolic detoxification system and method | |
| WO2018201862A1 (en) | Circulating tumor cell capture device | |
| CN110478548A (en) | Bioartificial liver system | |
| CN211512854U (en) | Bioartificial liver system | |
| Naruse et al. | Efficacy of a bioreactor filled with porcine hepatocytes immobilized on nonwoven fabric for ex vivo direct hemoperfusion treatment of liver failure in pigs | |
| CN110499289A (en) | The extracting method of PBMC in a kind of tunica albuginea layer filter | |
| CN206342739U (en) | Connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices | |
| CN206167487U (en) | Connection in series -parallel blood treatment device containing blood cell separator and blood plasma separator | |
| CN206342738U (en) | Series connection blood processor comprising plasma separator and cyto-centrifuge | |
| US5571082A (en) | Method of producing therapeutic effect upon an organism to reduce the pathologic lymphocyte population | |
| CN206151973U (en) | Blood treatment device and be used for operating device's control system | |
| CN206342737U (en) | Connection in series-parallel blood processor comprising cyto-centrifuge and bilirubin adsorption device | |
| CN208770520U (en) | Combination type biological Artificial Liver Support System | |
| CN206151972U (en) | Bioartificial liver processing apparatus and blood cell separator 's series connection blood processing apparatus and control system thereof | |
| CN109735447A (en) | It is a kind of for separating the devices and methods therefor of islet tissue | |
| CN105727382B (en) | A kind of continous way CRRT machine capability bascules of two tripper | |
| CN105536085B (en) | A kind of continous way CRRT machine capability bascules | |
| CN112604051A (en) | Total-liver type bioartificial liver system | |
| CN107617105A (en) | Suppress Treg cytoactives and promote application of the material of Tfh cell differentiations in HBV infection is treated | |
| US20040059275A1 (en) | Fat extraction | |
| CN111110738A (en) | Chinese medicinal preparation of caulis millettiae speciosae, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191126 Address after: 100039 No.100 courtyard, West 4th Ring Middle Road, Fengtai District, Beijing Patentee after: Fifth Medical Center, General Hospital of the Chinese People's Liberation Army Address before: 100039 Department of liver decay, No.302 Hospital, PLA, No. 100 West Fourth Ring Road, Beijing, Fengtai District, China Co-patentee before: Zhu Bing Patentee before: You Shaoli |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170721 Termination date: 20210712 |